MRNA·Moderna, Inc.

The FDA will review Moderna's mRNA flu vaccine application, reversing its initial rejection, which has buoyed the stock. This change, following a Type A meeting, could lead to the vaccine's availability before the next flu season, with a target review completion date of August 5th. This positive development suggests potential for future revenue streams and signals progress for Moderna's mRNA technology beyond COVID-19. However, the initial rejection, due to concerns about the clinical trial design or the comparator vaccine used, highlights the risks associated with vaccine investment. Simultaneously, Moderna has lost two defenses in a patent fight, which could affect future revenue streams. Traders should monitor the FDA's review progress and the legal proceedings, as both could significantly impact the company's outlook.